Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients
Phase 4
Withdrawn
- Conditions
- Diabetes
- Interventions
- Procedure: Surgical Treatment
- Registration Number
- NCT00596973
- Lead Sponsor
- Medtronic - MITG
- Brief Summary
The aim of this study is to assess the short term success and feasibility of ileal transposition with sleeve gastrectomy in non-morbidly obese patients with poorly controlled Type 2 Diabetes Mellitus
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosed Type 2 Diabetes for 3 to 5 years.
- Poorly controlled blood sugar despite standard of care* as demonstrated by HbA1c 8-11 for at least 6 months and 3 office visits. Standard of care is based on the ADA (American Diabetes Association) guidelines which include nutrition, exercise, education, behavior modification and pharmacological treatment. A co-investigator endocrinologist will ensure that the above standard of care has been met.
- BMI between 25.0 and 34.4.
- Stable weight as determined by no more than a 3% change in body weight in the last 3 months.
- Age between 35 and 65 (both men and women will be included).
- Able to provide Informed Consent.
- Able to comply with follow-up procedures.
Exclusion Criteria
- Previous history of major abdominal surgery which may lead to a hostile abdomen.
- Pregnancy
- Patients who have an incurable malignant or debilitating disease
- Serious uncorrectable impairment of coagulation (INR>1.4, PTT > + 3 secs), lungs, kidney or heart
- Diagnosed severe eating disorder
- Use of medication for weight loss in the last 6 months
- Untreated endocrine disorder
- Active peptic ulcer
- Untreated H. pylori
- Cognitive Impairment
- Diabetic autonomic neuropathy
- Symptomatic gastroparesis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ileal transposition with SG Surgical Treatment Procedure: Surgical Treatment
- Primary Outcome Measures
Name Time Method Treatment sucess based on patients' glycemic control 12 Months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mount Sinai School of Medicine
🇺🇸New York, New York, United States